164O Health-related quality of life (HRQoL) with pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as 1L treatment for advanced triple-negative breast cancer (TNBC): Results from KEYNOTE-355

164O Health-related quality of life (HRQoL) with pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as 1L treatment for advanced triple-negative breast cancer (TNBC): Results from KEYNOTE-355

Saved in:
Bibliographic Details
Published in:Annals of oncology Vol. 33; pp. S197 - S198
Main Authors: Cescon, D.W., Schmid, P., Rugo, H.S., Im, S-A., Md Yusof, M., Gallardo, C.E., Lipatov, O., Barrios, C.H., Perez Garcia, J.M., Iwata, H., Masuda, N., Torregroza Otero, M.A., Gokmen, E., Loi, S., Haiderali, A., Zhou, X., Guo, Z., Martin Nguyen, A., Cortés, J.
Format: Journal Article
Language:English
Published: Elsevier Ltd 01-05-2022
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:0923-7534
1569-8041
DOI:10.1016/j.annonc.2022.03.183